Previous 10 | Next 10 |
The following slide deck was published by Recursion Pharmaceuticals, Inc. in conjunction with this event. For further details see: Recursion Pharmaceuticals (RXRX) presents at 41st Annual J.P. Morgan Healthcare Conference - Slideshow
Recursion Pharmaceuticals press release ( NASDAQ: RXRX ): Q3 GAAP EPS of -$0.35 beats by $0.01 . Revenue of $13.16M (+420.2% Y/Y) beats by $6.31M . For further details see: Recursion Pharmaceuticals GAAP EPS of -$0.35 beats by $0.01, revenue of $13.16M be...
Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results PR Newswire Initiated our Phase 2 clinical trial for the potential treatment of familial adenomatous polyposis (FAP) Initiated our Phase 1 clinical trial for the potential treatmen...
Summary Baillie Gifford’s 13F portfolio value decreased from ~$97.51B to ~$96.99B this quarter. They increased Shopify, Roblox, Zoom Video, and Twilio while reducing Albemarle Corporation and Li Auto ADR. The top three positions are Tesla Motors, Moderna, and MercadoLib...
Recursion ( NASDAQ: RXRX ) has entered into a stock purchase agreement for the sale of an aggregate of ~15.3M shares of its common stock in a private placement, led by Kinnevik AB. The price per share of $9.80 reflects an ~7% discount to the volume weighted average sh...
Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB PR Newswire SALT LAKE CITY , Oct. 25, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug dis...
Summary Stanley Druckenmiller’s 13F portfolio value decreased from $2.65B to $1.63B this quarter. Duquesne added Eli Lilly and CrowdStrike while reducing Microsoft, Freeport-McMoRan, and Teck Resources. They also dropped Amazon.com. The top three positions are at ~34% o...
Summary Today, we put a clinical stage biotech concern called Recursion Pharmaceuticals, Inc. in the spotlight for the first time. The stock rapidly fell into Busted IPO territory since its debut on the market but has several drug candidates in its pipeline. The company has de...
Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022 PR Newswire Recursion initiates TUPELO, a Phase 2 trial of REC-4881 for the potential treatment of Familial Adenomatous Polyposis (FAP) Recursion initiates a Phase 1 trial for the potent...
The biotech industry is heavily regulated by the federal government and its science watchdog, the Food and Drug Administration (FDA). As a consequence, biotech investors often evaluate a possible investment by looking at the company's pipeline of future assets. Research and development is a...
News, Short Squeeze, Breakout and More Instantly...
Recursion Pharmaceuticals Inc. Company Name:
RXRX Stock Symbol:
NASDAQ Market:
Recursion Pharmaceuticals Inc. Website:
2024-07-27 05:41:00 ET Investors looking for stocks that can make dramatic gains often turn toward the biotechnology sector. It isn't unusual for stocks in this industry to shoot higher in response to positive clinical-trial results for experimental new drugs. Recursion Pharmaceutical...
2024-07-13 09:29:00 ET Recursion Pharmaceuticals (NASDAQ: RXRX) is arguably one of the most unique drugmakers on the planet. Though it's classified as a biotech company, its claim to fame is an artificial intelligence (AI)-based approach to speeding up drug discovery and development...
2024-07-11 10:10:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at transformative innovation in biopharma, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmac...